Purchase Order 75N93019P00810
Award Date
8/9/19
Potential Completion Date
9/25/21
Potential Value
$200K
Federal Agency
National Institute of Allergy and Infectious Diseases
Awardee
Advanced Bioadjuvants, LLC
Ultimate Awardee
Not listed
PSC Category
R499 - Support- Professional: Other
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Not Competed under SAP
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Omaha, NE 68135, USA
Solicitation Procedures
Simplified Acquisition
Number Of Offers Received
1
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
The Department of Health and Human Services' National Institutes of Health National Institute of Allergy and Infectious Diseases awarded a $375,000 firm fixed price purchase order to Advanced Bioadjuvants, LLC of Omaha, Nebraska. The three-year contract, running from September 2021 through September 2024, provides a non-exclusive license to Advanced Bioadjuvants' Adjuplex adjuvant technology. This will allow the National Institute of Allergy and Infectious Diseases to manufacture cGMP grade...
The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), awarded a $33,273,522 cost-plus-fixed-fee definitive contract to Anivive Lifesciences Inc., a self-certified small disadvantaged business, to develop vaccine candidates for biodefense and emerging infectious diseases. This contract, awarded on June 7, 2024, is part of NIAID's Broad Agency Announcement (BAA) research program and has a completion date of June 1, 2026. The contract...
This $599,526 Firm Fixed Price contract was awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. Department of Health and Human Services, to Enepret Incorporated, a for-profit manufacturer located in Lexington, Kentucky. The contract is for "Adjuvant Discovery and Down-Selection for Vaccines against Infectious and Immune-Mediated Diseases" and supports NIAID's broader program goals related to "A More Durable and Universal Adjuvanted...
The Department of Health and Human Services National Institutes of Health National Institute of Allergy and Infectious Diseases awarded a $224,992 firm fixed price definitive contract to Hafion Inc., a self-certified small disadvantaged and woman-owned small business, to conduct research and development on generating synergy between protein and non-protein macromolecular adjuvants. The contract, which was not set aside, was completed in July 2018. Hafion has also received other prime and...
This is a $4,259,653.00 definitive contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH) within the Department of Health and Human Services (HHS), to Inimmune Corp, a biotechnology company, for the development of a synthetic AS01-like adjuvant system for influenza vaccines. The contract has an ultimate completion date of September 29, 2028 and is a cost-type contract without a fee. This contract is not set aside for...
This federal contract award, valued at $2,857,893.00, was issued by the National Institute of Allergy and Infectious Diseases (NIAID), a component of the U.S. Department of Health and Human Services, to Advanced Bioscience Laboratories, Inc. (ABL) for the production of aluminum-based adjuvants. The contract is a Delivery Order under the NIAID Preclinical Development Support program, with a cost-plus-fixed-fee pricing type. ABL, a for-profit manufacturer of goods, has extensive experience...
This federal contract award was issued by the National Institute of Allergy and Infectious Diseases (NIAID), a component of the National Institutes of Health (NIH), to Advanced Bioscience Laboratories, Inc. (ABL), a leading contract research and manufacturing organization. The $548,977.00 cost-plus-fixed-fee contract is for the delivery of services in support of NIAID's infectious disease research and product development initiatives. This award is a task order under an existing Indefinite...
This federal contract award is for the PRODUCTION OF ADJUVANTS by Advanced Bioscience Laboratories, Inc. (ABL), a for-profit organization and manufacturer of goods. The contract, valued at $1,458,936.50, was awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a component of the National Institutes of Health (NIH) within the Department of Health and Human Services (HHS). The contract is a Delivery Order with a Cost Plus Fixed Fee pricing type, with an ultimate completion...
The National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency, awarded a $49,946.10 firm-fixed-price purchase order contract for antibody expression services to Biointron Biological USA Inc., a small disadvantaged business. The contract, which has no set-aside designation, has an ultimate completion date of July 11, 2025. The award was made on July 12, 2024. NIAID is responsible for conducting and supporting research to understand, treat, and prevent infectious and...
Adjuvax LLC has been awarded a $600,000 firm fixed price definitive contract by the National Institutes of Health's National Institute of Allergy and Infectious Diseases to optimize the formulation of a virus-like particle adjuvant under a Small Business Innovation Research solicitation. The solicitation sought proposals across technical topics aligned with NIH and CDC missions to develop medical technologies and other solutions to advance public health. This opportunity was set aside for...